Immunotherapeutic targets in non-small cell lung cancer.
Sadeghirad, H
Bahrami, T
Layeghi, SM
Yousefi, H
Rezaei, M
Hosseini-Fard, SR
Radfar, P
Warkiani, ME
O'Byrne, K
Kulasinghe, A
- Publisher:
- WILEY
- Publication Type:
- Journal Article
- Citation:
- Immunology, 2023, 168, (2), pp. 256-272
- Issue Date:
- 2023-02
Open Access
Copyright Clearance Process
- Recently Added
- In Progress
- Open Access
This item is open access.
Full metadata record
Field | Value | Language |
---|---|---|
dc.contributor.author | Sadeghirad, H | |
dc.contributor.author | Bahrami, T | |
dc.contributor.author | Layeghi, SM | |
dc.contributor.author | Yousefi, H | |
dc.contributor.author | Rezaei, M | |
dc.contributor.author | Hosseini-Fard, SR | |
dc.contributor.author | Radfar, P | |
dc.contributor.author | Warkiani, ME | |
dc.contributor.author | O'Byrne, K | |
dc.contributor.author | Kulasinghe, A | |
dc.date.accessioned | 2023-03-14T23:16:47Z | |
dc.date.available | 2022-08-02 | |
dc.date.available | 2023-03-14T23:16:47Z | |
dc.date.issued | 2023-02 | |
dc.identifier.citation | Immunology, 2023, 168, (2), pp. 256-272 | |
dc.identifier.issn | 0019-2805 | |
dc.identifier.issn | 1365-2567 | |
dc.identifier.uri | http://hdl.handle.net/10453/167332 | |
dc.description.abstract | Non-small cell lung cancer (NSCLC) is one of the most common types of cancer in the world and has a 5-year survival rate of ~20%. Immunotherapies have shown promising results leading to durable responses, however, they are only effective for a subset of patients. To determine the best therapeutic approach, a thorough and in-depth profiling of the tumour microenvironment (TME) is required. The TME is a complex network of cell types that form an interconnected network, promoting tumour cell initiation, growth and dissemination. The stroma, immune cells and endothelial cells that comprise the TME generate a plethora of cytotoxic or cytoprotective signalling pathways. In this review, we discuss immunotherapeutic targets in NSCLC tumours and how the TME may influence patients' response to immunotherapy. | |
dc.format | Print-Electronic | |
dc.language | eng | |
dc.publisher | WILEY | |
dc.relation.ispartof | Immunology | |
dc.relation.isbasedon | 10.1111/imm.13562 | |
dc.rights | info:eu-repo/semantics/openAccess | |
dc.subject | 1107 Immunology, 1114 Paediatrics and Reproductive Medicine | |
dc.subject.classification | Immunology | |
dc.subject.mesh | Humans | |
dc.subject.mesh | Carcinoma, Non-Small-Cell Lung | |
dc.subject.mesh | Lung Neoplasms | |
dc.subject.mesh | Endothelial Cells | |
dc.subject.mesh | Immunotherapy | |
dc.subject.mesh | Antineoplastic Agents | |
dc.subject.mesh | Tumor Microenvironment | |
dc.subject.mesh | Endothelial Cells | |
dc.subject.mesh | Humans | |
dc.subject.mesh | Carcinoma, Non-Small-Cell Lung | |
dc.subject.mesh | Lung Neoplasms | |
dc.subject.mesh | Antineoplastic Agents | |
dc.subject.mesh | Immunotherapy | |
dc.subject.mesh | Tumor Microenvironment | |
dc.subject.mesh | Humans | |
dc.subject.mesh | Carcinoma, Non-Small-Cell Lung | |
dc.subject.mesh | Lung Neoplasms | |
dc.subject.mesh | Endothelial Cells | |
dc.subject.mesh | Immunotherapy | |
dc.subject.mesh | Antineoplastic Agents | |
dc.subject.mesh | Tumor Microenvironment | |
dc.title | Immunotherapeutic targets in non-small cell lung cancer. | |
dc.type | Journal Article | |
utslib.citation.volume | 168 | |
utslib.location.activity | England | |
utslib.for | 1107 Immunology | |
utslib.for | 1114 Paediatrics and Reproductive Medicine | |
pubs.organisational-group | /University of Technology Sydney | |
pubs.organisational-group | /University of Technology Sydney/Faculty of Engineering and Information Technology | |
pubs.organisational-group | /University of Technology Sydney/Strength - CHT - Health Technologies | |
pubs.organisational-group | /University of Technology Sydney/Faculty of Engineering and Information Technology/School of Biomedical Engineering | |
pubs.organisational-group | /University of Technology Sydney/Strength - IBMD - Initiative for Biomedical Devices | |
pubs.organisational-group | /University of Technology Sydney/Centre for Health Technologies (CHT) | |
utslib.copyright.status | open_access | * |
dc.date.updated | 2023-03-14T23:16:45Z | |
pubs.issue | 2 | |
pubs.publication-status | Published | |
pubs.volume | 168 | |
utslib.citation.issue | 2 |
Abstract:
Non-small cell lung cancer (NSCLC) is one of the most common types of cancer in the world and has a 5-year survival rate of ~20%. Immunotherapies have shown promising results leading to durable responses, however, they are only effective for a subset of patients. To determine the best therapeutic approach, a thorough and in-depth profiling of the tumour microenvironment (TME) is required. The TME is a complex network of cell types that form an interconnected network, promoting tumour cell initiation, growth and dissemination. The stroma, immune cells and endothelial cells that comprise the TME generate a plethora of cytotoxic or cytoprotective signalling pathways. In this review, we discuss immunotherapeutic targets in NSCLC tumours and how the TME may influence patients' response to immunotherapy.
Please use this identifier to cite or link to this item:
Download statistics for the last 12 months
Not enough data to produce graph